OralTopicalDosed ingredientTherapeutic flag

Nicotine

CAS 54-11-5

Nicotine (CAS 54-11-5) is a Phase 4 pharmaceutical compound with 28 bioactivity targets and 1,039 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral

Adverse signals

1,039

SOURCE IUPHAR/BPS

PubMed IDs

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Nicotine

CAS Number

54-11-5

UNII

6M3C89ZY6R

InChIKey

SNICXCGAKADSCV-JTQLQIEISA-N

ChEMBL ID

CHEMBL3

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

dosed ingredientnatural productoraltherapeutic flagtopical

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)

Approved or marketed human pharmaceutical use is represented in the source phase field.

ChEMBL CHEMBL3 | Small molecule

SOURCE EMBL-EBI ChEMBL 48 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	Ki	1639.901333152174 nM	348	-
-	EC50	13601.846428571429 nM	89	-
-	IC50	5452.375151515152 nM	63	-
-	AC50	29733.396666666667 nM	30	-
-	Potency	17791.785294117646 nM	23	-
-	Kd	7104.335411764706 nM	13	-
Neuronal acetylcholine receptor subunit alpha-7 Ion channel	Ki	5.39	-	Homo sapiens
Potassium voltage-gated channel subfamily D member 3 Ion channel	IC50	7.4	-	Homo sapiens
Cytochrome P450 2A6 Enzyme	IC50	5.356	-	Homo sapiens
Acetylcholine-binding protein Unclassified	Ki	7.2	-	Lymnaea stagnalis
Transient receptor potential cation channel subfamily A member 1 Ion channel	EC50	4.8	-	Homo sapiens
Acetylcholine receptor subunit delta Ion channel	Ki	9	-	Torpedo californica
Neuronal acetylcholine receptor subunit alpha-4 Ion channel	Ki	9.03	-	Rattus norvegicus
Neuronal acetylcholine receptor subunit alpha-7 Ion channel	Ki	6.89	-	Rattus norvegicus
Neuronal acetylcholine receptor subunit alpha-7 Ion channel	Ki	6.61	-	Mus musculus
Neuronal acetylcholine receptor subunit alpha-9 Ion channel	Kd	8.3	-	Rattus norvegicus
Neuronal acetylcholine receptor subunit beta-4 Ion channel	Ki	7.14	-	Rattus norvegicus
Neuronal acetylcholine receptor subunit alpha-3 Ion channel	Ki	7.33	-	Rattus norvegicus
Neuronal acetylcholine receptor subunit alpha-2 Ion channel	Ki	7.92	-	Rattus norvegicus
Soluble acetylcholine receptor Unclassified	Ki	7.52	-	Aplysia californica
Acetylcholine receptor subunit alpha Ion channel	IC50	4.64	-	Torpedo californica
Lycopene cyclase Enzyme	IC50	5.32	-	Pantoea ananas
Nicotinic acetylcholine receptor alpha 5 subunit Ion channel	Ki	5.61	-	Musca domestica
Acetylcholine receptor subunit beta-like 2 Ion channel	Ki	5.57	-	Drosophila melanogaster
Neuronal acetylcholine receptor subunit alpha-4 Ion channel	Ki	8.72	-	Gallus gallus
Neuronal acetylcholine receptor subunit alpha-4 Ion channel	IC50	8.15	-	Mus musculus
Neuronal acetylcholine receptor; alpha2/beta2 Ion channel	Ki	8.26	-	Rattus norvegicus
Neuronal acetylcholine receptor; alpha3/beta2 Ion channel	Ki	9	-	Rattus norvegicus
Neuronal acetylcholine receptor; alpha3/beta4 Ion channel	Ki	6.7	-	Rattus norvegicus
Neuronal acetylcholine receptor; alpha4/beta2 Ion channel	Kd	9.4	-	Rattus norvegicus
Neuronal acetylcholine receptor; alpha4/beta4 Ion channel	Ki	8.26	-	Rattus norvegicus
Neuronal acetylcholine receptor; alpha2/beta4 Ion channel	Ki	7.15	-	Homo sapiens
Neuronal acetylcholine receptor Ion channel	Kd	11	-	Rattus norvegicus
Neuronal acetylcholine receptor; alpha2/beta2 Ion channel	Ki	8.26	-	Homo sapiens
Neuronal acetylcholine receptor; alpha4/beta2 Ion channel	Ki	8.56	-	Homo sapiens
Neuronal acetylcholine receptor; alpha3/beta4 Ion channel	Ki	5.95	-	Homo sapiens
Neuronal acetylcholine receptor; alpha3/beta2 Ion channel	Ki	7.854	-	Homo sapiens
Neuronal acetylcholine receptor; alpha4/beta4 Ion channel	Ki	7.64	-	Homo sapiens
Serotonin 3 (5-HT3) receptor Ion channel	Ki	4.15	-	Homo sapiens
Acetylcholine receptor; alpha1/beta1/delta/gamma Ion channel	Ki	5.83	-	Homo sapiens
Neuronal acetylcholine receptor; alpha3/alpha6/beta2/beta3 Ion channel	IC50	7.07	-	Homo sapiens
Neuronal acetylcholine receptor; alpha2/beta4 Ion channel	Ki	7.15	-	Rattus norvegicus
Acetylcholine receptor Ion channel	Ki	5.2	-	Torpedo californica
Muscarinic acetylcholine receptor GPCR	IC50	4.55	-	Rattus norvegicus
Acetylcholine receptor subunit alpha Ion channel	IC50	4.68	-	Homo sapiens
Neuronal acetylcholine receptor subunit alpha-3 Ion channel	IC50	7.35	-	Homo sapiens
Transient receptor potential cation channel subfamily A member 1 Ion channel	EC50	5	-	Mus musculus
Potassium voltage-gated channel subfamily D member 3 Ion channel	IC50	7.4	-	Rattus norvegicus

SOURCE DrugCentral 80 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PT	Drug AE	LLR	MedDRA
Nicotine dependence	213	1069.634	10057852
Macular degeneration	372	962.402	10025409
Drug withdrawal syndrome neonatal	199	643.089	10013756
Foetal exposure during pregnancy	406	552.523	10071404
Drug dependence	293	544.825	10013663
Incorrect product administration duration	179	431.698	10081581
Overdose	401	319.3	10033295
Product adhesion issue	111	308.422	10069889
Premature baby	219	302.312	10036590
Intentional product misuse	262	275.62	10074903
Premature delivery	137	215.378	10036595
Dependence	64	189.079	10012335
Accidental overdose	146	188.525	10000381
Low birth weight baby	109	185.933	10067508
Rhesus incompatibility	36	182.481	10063676
Chronic sinusitis	95	173.307	10009137
Truncus arteriosus persistent	43	169.54	10044703
Maternal exposure during breast feeding	67	155.487	10080752
Paraesthesia oral	101	153.323	10057372
Jaundice neonatal	50	142.921	10023138
Application site erythema	64	141.963	10003041
Application site pruritus	58	139.112	10003053
Procedural pain	97	134.981	10064882
Tobacco abuse	37	125.781	10043903
Drug abuse	221	122.388	10013654
Poor feeding infant	36	119.981	10075316
Exposure via breast milk	50	115.588	10080751
Foetal disorder	37	108.87	10061157
Myocardial stunning	22	103.637	10072186
Vaginal flatulence	41	101.747	10064227
Maternal exposure during pregnancy	247	95.685	10071408
Toxicity to various agents	378	93.28	10070863
Congenital cardiovascular anomaly	30	92.666	10061054
Application site rash	38	91.518	10003054
Ventricular septal defect	55	88.49	10047298
Cardiac septal defect	28	84.917	10064021
Rheumatoid arthritis	9	82.824	10039073
Tobacco poisoning	17	81.746	10068887
Rib deformity	20	81.641	10059011
Alcohol abuse	43	80.835	10001584
Product quality issue	99	78.068	10069327
Alopecia	23	77.111	10001760
Vaginal discharge	46	76.854	10046901
Drug intolerance	26	74.35	10061822
Substance abuse	50	73.467	10066169
Drug screen positive	41	71.571	10049177
Female genital tract fistula	41	71.335	10061149
Agitation neonatal	26	69.389	10001500
Neutropenia neonatal	22	68.088	10029358
Arthropathy	11	67.992	10003285

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE IUPHAR/BPS 7 interactions

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

Target	Action	Affinity	PubMed
K v 4.3 Kcnd3	Channel blocker	7.4 pIC50	10973847
TRPA1 TRPA1	Activation	4.800000190734863 pEC50	19749751
nicotinic acetylcholine receptor α10 subunit CHRNA10	Antagonist	-	-
nicotinic acetylcholine receptor α3 subunit CHRNA3	Agonist	5.760000228881836 pKi	32026697
nicotinic acetylcholine receptor α4 subunit CHRNA4	Agonist	8.65999984741211 pKi	32026697
nicotinic acetylcholine receptor α9 subunit CHRNA9	Antagonist	-	-
nicotinic acetylcholine receptor α9 subunit CHRNA9	Antagonist	-	-

SOURCE PharmGKB 60 phenotype rows

Pharmacogenomics

Drug-gene phenotype annotations and evidence levels from PharmGKB-mapped rows.

CYP2A6 (PA121) CYP2A6*1A, CYP2A6*2, CYP2A6*9, CYP2A6*17

CYP2A6 *1A/*2 + *1A/*9 + *1A/*17 (assigned as reduced metabolizers phenotype) are associated with decreased metabolism of nicotine in healthy individuals as compared to CYP2A6 *1A/*1A (assigned as normal metabolizers phenotype) .

Evidence: -; PMID 30706508

OPRM1 (PA31945) rs1799971

Genotype AA is associated with increased likelihood of smoking cessation when treated with nicotine as compared to genotypes AG + GG.

Evidence: -; PMID 17224915

CYP2A6 (PA121) CYP2A6*1A, CYP2A6*9A, CYP2A6*17, CYP2A6*20, CYP2A6*24A, CYP2A6*26, CYP2A6*27

CYP2A6 *20 + *26 + *24A+ *9A + *27 + *17 is associated with decreased metabolism of nicotine as compared to CYP2A6 *1A.

Evidence: -; PMID 18360915

ANKK1 (PA134872551) rs1800497

Genotypes AA + AG is associated with increased likelihood of smoking cessation when treated with nicotine in people with female gender as compared to genotype GG.

Evidence: -; PMID 15033882

ANKK1 (PA134872551) rs1800497

Allele A is associated with smoking cessation when treated with nicotine in people with Depression as compared to genotype GG.

Evidence: -; PMID 21540761

CHRNA3 (PA113) rs1051730

Allele A is associated with increased risk of Tobacco Use Disorder when exposed to nicotine as compared to allele G.

Evidence: -; PMID 20886544

CYP2A6 (PA121) CYP2A6*1A, CYP2A6*9A

CYP2A6 *9A/*9A is associated with decreased metabolism of nicotine as compared to CYP2A6 *1A/*9A + *1A/*1A.

Evidence: -; PMID 12844137

CYP2A6 (PA121) CYP2A6*1A, CYP2A6*4A, CYP2A6*9A

CYP2A6 *4A/*9A is associated with decreased metabolism of nicotine as compared to CYP2A6 *1A/*4A.

Evidence: -; PMID 12844137

CYP2A6 (PA121) CYP2A6*1A, CYP2A6*20

CYP2A6 *20 is associated with decreased metabolism of coumarin and nicotine in healthy individuals as compared to CYP2A6 *1A.

Evidence: -; PMID 15993850

CYP2A6 (PA121) CYP2A6*1A, CYP2A6*4A

CYP2A6 *4A/*4A is associated with decreased metabolism of nicotine as compared to CYP2A6 *1A/*1A.

Evidence: -; PMID 11779172

CHRNA5 (PA26491) rs67624739

Allele del is not associated with Tobacco Use Disorder when exposed to nicotine as compared to allele CAGAGGGAAATAGGGGCGGGGC.

Evidence: -; PMID 29196725

CYP2A6 (PA121) CYP2A6*1A, CYP2A6*4A

CYP2A6 *4A is associated with decreased metabolism of nicotine as compared to CYP2A6 *1A.

Evidence: -; PMID 12445030

CHRNA5 (PA26491) rs67624739

Allele del is not associated with response to bupropion, nicotine and varenicline in people with Tobacco Use Disorder as compared to allele CAGAGGGAAATAGGGGCGGGGC.

Evidence: -; PMID 29196725

CYP2A6 (PA121) CYP2A6*1A, CYP2A6*4A, CYP2A6*9A, CYP2A6*10

CYP2A6 *4A + *10 + *9A is associated with decreased plasma and urinary ratio of metabolites trans-3'-hydroxycotinine to cotinine (3HC/COT) when exposed to nicotine in healthy individuals as compared to CYP2A6 *1A.

Evidence: -; PMID 22569203

OPRM1 (PA31945) rs1799971

Genotypes AG + GG is associated with increased smoking due to nicotine in children as compared to genotype AA.

Evidence: -; PMID 22260295

DRD2 (PA27478) rs1800497

Genotypes AA + AG is associated with increased craving of nicotine in children as compared to genotype GG.

Evidence: -; PMID 26449981

DRD2 (PA27478) rs1800497

Genotype GG is associated with increased severity of craving when exposed to nicotine in children as compared to genotypes AA + AG.

Evidence: -; PMID 26449981

OPRM1 (PA31945) rs1799971

Allele G is not associated with craving of nicotine in children as compared to allele A.

Evidence: -; PMID 26449981

OPRM1 (PA31945) rs1799971

Allele G is not associated with risk of Tobacco Use Disorder due to nicotine as compared to allele A.

Evidence: -; PMID 22046326

CHRNA5 (PA26491) rs16969968

Allele A is not associated with risk of Tobacco Use Disorder due to nicotine as compared to allele G.

Evidence: -; PMID 22046326

CHRM2 (PA111) rs1824024

Allele C is not associated with risk of Tobacco Use Disorder due to nicotine as compared to allele A.

Evidence: -; PMID 19644963

ARRB2 (PA60) rs4790694

Allele A is not associated with increased risk of Tobacco Use Disorder due to nicotine as compared to allele C.

Evidence: -; PMID 17579607

CYP2A13 (PA27101) rs8192789

Allele T is not associated with risk of Tobacco Use Disorder due to nicotine as compared to allele C.

Evidence: -; PMID 22046326

CYP2A6 (PA121) rs28399433

Allele C is associated with decreased expression of enzyme contributing to the metabolism of coumarin and nicotine.

Evidence: -; PMID 11394901

CYP2A6 (PA121) rs28399433

Genotype CC is associated with decreased severity of Tobacco Use Disorder due to nicotine as compared to genotypes AA + AC.

Evidence: -; PMID 22046326

CHRNB3 (PA26495) rs6474413

Allele T is not associated with severity of Tobacco Use Disorder due to nicotine as compared to allele C.

Evidence: -; PMID 29621993

CHRNA5 (PA26491) rs667282

Allele C is not associated with severity of Tobacco Use Disorder due to nicotine in men as compared to allele T.

Evidence: -; PMID 29666375

CHRNA10 (PA26488) rs4575304

Allele G is not associated with response to nicotine in women as compared to allele A.

Evidence: -; PMID 20231857

CYP2A6 (PA121) rs5031016

Allele G is associated with decreased metabolism of nicotine as compared to allele A.

Evidence: -; PMID 11779172

ANKK1 (PA134872551) rs1800497

Genotypes AA + AG is associated with increased likelihood of cessation when treated with nicotine as compared to genotype GG.

Evidence: -; PMID 15077009

SOURCE NLM RxNorm 3 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

Name	RxCUI	Type	Source
NICOTINE	7407	SU	MTHSPL
Nicotine	7407	SU	MTHSPL
nicotine	7407	IN	RXNORM

SOURCE SIDER 80 side-effect rows

Side Effects

SIDER side-effect terms mapped to the drug or same-CAS compound identity.

Side Effect	Drug Name	MedDRA Type	Concept ID
Abdominal discomfort	nicotine	PT	C0232487
Abdominal discomfort	nicotine	PT	C0232487
Abdominal pain	nicotine	LLT	C0000737
Abdominal pain	nicotine	PT	C0000737
Abdominal pain upper	nicotine	LLT	C0232492
Abdominal pain upper	nicotine	PT	C0232492
Abnormal dreams	nicotine	PT	C0234458
Abnormal faeces	nicotine	LLT	C0162287
Abnormal faeces	nicotine	PT	C0162287
Abnormal vision	nicotine	LLT	C3665386
Acne	nicotine	LLT	C0702166
Acne	nicotine	PT	C0702166
Affect lability	nicotine	PT	C0233472
Agitation	nicotine	LLT	C0085631
Agitation	nicotine	PT	C0085631
Amnesia	nicotine	LLT	C0002622
Amnesia	nicotine	PT	C0002622
Anaphylactic shock	nicotine	LLT	C0002792
Anaphylactic shock	nicotine	PT	C0002792
Angioedema	nicotine	LLT	C0002994
Angioedema	nicotine	PT	C0002994
Anxiety	nicotine	LLT	C0003467
Anxiety	nicotine	PT	C0003467
Apathy	nicotine	LLT	C0085632
Apathy	nicotine	PT	C0085632
Aphasia	nicotine	LLT	C0003537
Aphasia	nicotine	PT	C0003537
Aphthous stomatitis	nicotine	LLT	C0038363
Aphthous stomatitis	nicotine	PT	C0038363
Aphthous stomatitis	nicotine	LLT	C0038363
Aphthous stomatitis	nicotine	PT	C0038363
Application site reaction	nicotine	LLT	C0151505
Application site reaction	nicotine	PT	C0151505
Arrhythmia	nicotine	LLT	C0003811
Arrhythmia	nicotine	PT	C0003811
Arthralgia	nicotine	LLT	C0003862
Arthralgia	nicotine	PT	C0003862
Arthritis	nicotine	LLT	C0003864
Arthritis	nicotine	PT	C0003864
Asthenia	nicotine	LLT	C0004093
Asthenia	nicotine	PT	C0004093
Asthenia	nicotine	PT	C0004093
Atrial fibrillation	nicotine	LLT	C0004238
Atrial fibrillation	nicotine	PT	C0004238
Atrial fibrillation	nicotine	LLT	C0004238
Atrial fibrillation	nicotine	PT	C0004238
Back pain	nicotine	LLT	C0004604
Back pain	nicotine	PT	C0004604
Bladder pain	nicotine	PT	C0232849
Blister	nicotine	LLT	C0005758
Blister	nicotine	PT	C0005758
Blood pressure fluctuation	nicotine	PT	C0549405
Blood pressure increased	nicotine	LLT	C0497247
Blood pressure increased	nicotine	PT	C0497247
Body temperature increased	nicotine	LLT	C0015967
Body temperature increased	nicotine	PT	C0015967
Bronchitis	nicotine	LLT	C0006277
Bronchitis	nicotine	PT	C0006277
Bronchospasm	nicotine	LLT	C0006266
Bronchospasm	nicotine	PT	C0006266
Burning sensation	nicotine	LLT	C0085624
Burning sensation	nicotine	PT	C0085624
Cardiac disorder	nicotine	LLT	C0018799
Cardiac disorder	nicotine	PT	C0018799
Cardiac failure	nicotine	LLT	C0018801
Cardiac failure	nicotine	PT	C0018801
Cerebration impaired	nicotine	LLT	C0235198
Change in blood pressure	nicotine	LLT	C1268766
Chest discomfort	nicotine	PT	C0235710
Chest discomfort	nicotine	LLT	C0235710
Chest discomfort	nicotine	PT	C0235710
Chest pain	nicotine	LLT	C0008031
Chest pain	nicotine	PT	C0008031
Chest pain	nicotine	PT	C0008031
Chest tightness	nicotine	LLT	C0232292
Cold sweat	nicotine	LLT	C0232431
Cold sweat	nicotine	PT	C0232431
Completed suicide	nicotine	PT	C0852733
Confusional state	nicotine	LLT	C0009676
Confusional state	nicotine	PT	C0009676

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Nicotine used for in pharmaceutical contexts?

Nicotine (CAS 54-11-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Nicotine?

Nicotine has 1,039 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Nicotine dependence, Macular degeneration, Drug withdrawal syndrome neonatal, Foetal exposure during pregnancy, Drug dependence. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Nicotine also used in cosmetics?

No same-CAS cosmetics profile is rendered from the ingredients-table cross-reference for Nicotine.

What clinical phase is Nicotine in?

Nicotine is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Nicotine?

Nicotine has 48 bioactivity rows in this page query. Rendered target entries include Neuronal acetylcholine receptor subunit alpha-7, Potassium voltage-gated channel subfamily D member 3, Cytochrome P450 2A6, Acetylcholine-binding protein, Transient receptor potential cation channel subfamily A member 1.